ClinConnect ClinConnect Logo
Search / Trial NCT05855499

Plasma on Chronic Wounds for Epidermal Regeneration

Launched by COLDPLASMATECH · May 3, 2023

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat chronic wounds on the lower legs using cold plasma therapy. Many people, especially those with diabetes or other health conditions, struggle with wounds that don’t heal properly. The trial aims to see if a special device that applies cold plasma over larger areas can help these wounds heal faster and better. Over four weeks, participants will receive this plasma treatment in addition to standard wound care, which is the usual method doctors recommend for treating such wounds.

To be eligible for the study, participants must be at least 18 years old and have a chronic wound that has not healed for at least eight weeks. The wound should be on the lower leg and measure between 5 to 100 square centimeters. Participants will be closely monitored throughout the study to see how well their wounds heal with this new treatment. It’s important to note that certain health conditions, such as infections or recent surgeries, may prevent someone from joining the trial. Overall, this study could provide valuable information about a promising new treatment for chronic wounds.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Inclusion criteria are divided into patient-specific and wound-specific criteria.
  • Patient Criteria:
  • Patient must be at least 18 years old (legal age) and legally competent
  • The patient has at least one diagnosed chronic (existing for at least 8 weeks), non-healing wound due to a UCA or UCV on the lower leg, below the knee
  • There is a signed consent form dated by the patient's own hand
  • Wound Criteria:
  • In case of multiple wounds, the largest wound by area will be included in the study if it meets all inclusion criteria and no exclusion criteria and is suitable for use of the investigational product. The target wound is at least 2 cm away from the other wound(s)
  • The wound was diagnosed - at the time of planned inclusion - more than 8 weeks ago and classified as a chronic wound
  • The initial wound area is 5 cm²-100 cm2
  • The wound can be enclosed completely by the plasma applicator (10 cm x 10 cm)
  • The wound is not undermined
  • The wound is located on the lower leg
  • Exclusion Criteria:
  • The exclusion criteria are divided into patient-specific and wound-specific criteria.
  • Patient Criteria:
  • The patient is younger than 18 years and/or lacks legal capacity
  • The patient has already participated in this study
  • The patient is already participating in another interventional study
  • Pregnant or breastfeeding patients
  • The patient has an implanted pacemaker, defibrillator or other active implants
  • The patient has a light/sun allergy
  • The patient has a silicone allergy
  • The patient has had a thrombosis within the last 3 months
  • The patient has a systemic and/or chronic infectious disease (e.g., HIV, tuberculosis, hepatitis)
  • The patient has a tumour disease
  • An ongoing or recently completed chemotherapy or radiotherapy
  • The patient is undergoing severe endogenous or drug immunosuppression
  • The patient is receiving systemic antibiotic treatment or is receiving/needing antiseptic/antibiotic wound therapy in/near the wound
  • The patient does not have the necessary revascularization (paVK)
  • The patient requires vital instrumental monitoring in the sense of "basic monitoring": near-patient respiratory gas measurement (oxygen, carbon dioxide and inhalation anaesthetic), pulse oximeter, ECG monitoring, blood pressure measurement (non-invasive), an oscillometric blood pressure measurement with automatic mode
  • Existing alcohol or drug abuse
  • The patient requires dialysis
  • Wound Criteria:
  • The wound is not a chronic wound as defined by study protocol
  • The wound is difficult to access or close to exposed vessels
  • The wound is critically colonized or infected
  • Acute infections in the wound area (radius 5 cm)
  • The wound is bleeding profusely. This does not include bleeding immediately after debridement
  • The wound is undermined
  • The wound is located at the knee or above

About Coldplasmatech

Coldplasmatech is a pioneering clinical trial sponsor at the forefront of advanced medical technologies, specializing in the development and application of cold plasma therapies for various health conditions. With a commitment to innovation and patient care, the organization focuses on harnessing the unique properties of cold plasma to promote wound healing, reduce infection rates, and improve overall treatment outcomes. Through rigorous clinical trials and research initiatives, Coldplasmatech aims to establish the efficacy and safety of its therapies, contributing to the evolving landscape of regenerative medicine and enhancing the quality of life for patients worldwide.

Locations

Hamburg, , Germany

Dresden, Sachsen, Germany

Berlin, , Germany

Tübingen, , Germany

Tübingen, Baden Württemberg, Germany

München, Bayern, Germany

Regensburg, Bayern, Germany

Bochum, Nordrhein Westfalen, Germany

Saalfeld, Thueringen, Germany

Patients applied

0 patients applied

Trial Officials

Robert Banaschik, Dr.

Study Director

Coldplasmatech

Isabel Zänker, Dr.

Principal Investigator

Thüringen-Kliniken

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported